Unknown Manufacturer
Tabelecleucel is a medication that uses Epstein-Barr virus (EBV)-specific allogeneic cytotoxic T cells to treat EBV-associated post-transplant lymphoproliferative disorder.
Tabelecleucel is a medication that uses Epstein-Barr virus (EBV)-specific allogeneic cytotoxic T cells to treat EBV-associated post-transplant lymphoproliferative disorder.
Human B cells are the main targets of Epstein-Barr virus (EBV). In immunocompetent people, EBV usually has mild effects, but in immunocompromised patients, an EBV infection can lead to potentially life-threatening consequences. For instance, patients that have gone through solid organ or bone marrow transplantation may develop EBV-associated post-transplant lymphoproliferative disorder (PTLD), a type of cancer or lymphoma caused by an uncontrolled growth of cells in lymph nodes and other organs. Tabelecleucel consists of EBV-specific allogeneic cytotoxic T cells (CTLs) that specifically target EBV-infected B-cells, helping to control EBV-associated cancers.
